StockNews.com started protection on shares of Neptune Wellness Options (NASDAQ:NEPT – Get Rating) (TSE:NTB) in a analysis word issued to buyers on Saturday. The brokerage set a “promote” ranking on the biotechnology firm’s inventory.
Neptune Wellness Solutions stock opened at $0.23 on Friday. The agency has a 50 day shifting common of $0.31 and a 200 day shifting common of $0.44. The agency has a market capitalization of $43.53 million, a price-to-earnings ratio of -0.41 and a beta of two.15. Neptune Wellness Options has a 12-month low of $0.21 and a 12-month excessive of $1.58. The corporate has a present ratio of 1.75, a fast ratio of 1.07 and a debt-to-equity ratio of 0.12.
Neptune Wellness Options (NASDAQ:NEPT – Get Rating) (TSE:NTB) final launched its earnings outcomes on Thursday, February tenth. The biotechnology firm reported ($0.09) earnings per share (EPS) for the quarter, lacking the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). The agency had income of $14.63 million in the course of the quarter, in comparison with analysts’ expectations of $13.64 million. Neptune Wellness Options had a damaging return on fairness of 73.19% and a damaging web margin of 207.14%. On common, analysts predict that Neptune Wellness Options will submit -0.32 EPS for the present 12 months.
Our prime analyst says that is the month that biotech makes a breakout transfer.
Our pals at Behind the Markets have recognized one inventory that’s set to show the biotech world on its head.
Get the total report at present earlier than its too late.
Plenty of institutional buyers and hedge funds have just lately made modifications to their positions in NEPT. Virtu Monetary LLC bought a brand new stake in Neptune Wellness Options in the course of the 4th quarter valued at roughly $64,000. Natixis bought a brand new stake in Neptune Wellness Options in the course of the third quarter valued at roughly $69,000. Goldman Sachs Group Inc. grew its holdings in Neptune Wellness Options by 981.0% in the course of the 2nd quarter. Goldman Sachs Group Inc. now owns 139,978 shares of the biotechnology firm’s inventory valued at $164,000 after shopping for an extra 127,029 shares within the final quarter. Morgan Stanley grew its holdings in Neptune Wellness Options by 31.8% in the course of the 2nd quarter. Morgan Stanley now owns 141,269 shares of the biotechnology firm’s inventory valued at $166,000 after shopping for an extra 34,123 shares within the final quarter. Lastly, Renaissance Applied sciences LLC bought a brand new stake in Neptune Wellness Options in the course of the 4th quarter valued at roughly $184,000. 11.72% of the inventory is owned by institutional buyers and hedge funds.
Neptune Wellness Options Firm Profile (Get Rating)
Neptune Wellness Options Inc, a well being and wellness merchandise firm, specializes within the extraction, purification and formulation of hashish merchandise, in addition to different specialty substances, corresponding to MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and numerous different marine and seed oils.
Featured Articles
This prompt information alert was generated by narrative science expertise and monetary information from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to [email protected]
Should you invest $1,000 in Neptune Wellness Solutions right now?
Earlier than you contemplate Neptune Wellness Options, you may wish to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers each day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Neptune Wellness Options wasn’t on the checklist.
Whereas Neptune Wellness Options at present has a “Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
